ASCO 2022 on EFS by Residual Cancer Burden After Neoadjuvant Pembro + Chemo vs. Placebo + Chemo for eTNBC: Exploratory Analysis From the KEYNOTE-522

June 14, 2022

3 Comments
Login to view comments. Click here to Login